«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2021年06期

页码:

741-744

栏目:

论著

出版日期:

2021-12-20

文章信息/Info

Title:

Clinical characteristics and risk factors of chronic obstructive pulmonary disease with tuberculosis

作者:

万鹏飞¹; 徐 静²; 陈华萍¹; 2; 胡明冬¹; 2

400037 重庆,陆军(第三)军医大学第二附属医院老年与特勤医学科¹、呼吸与危重症医学中心²

Author(s):

Wan Pengfei¹;  Xu Jing²;  Chen Huaping¹; 2;  Hu Mingdong¹; 2.

¹Department of Gerontology and Secret Service Medicine, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China; ²Department of respiratory and critical care medicine center, Xinqiao Hospital, Army Medical University, Chongqing 400037, China

关键词:

肺疾病; 慢性阻塞性;  肺结核;  临床特征;  危险因素

Keywords:

Chronic obstructive pulmonary disease;  Tuberculosis;  Clinical characteristics;  Risk factor

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2021.06.007

摘要:

目的 观察慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)合并肺结核的临床特征,分析其危险因素。方法 选择陆军军医大学第二附属医院呼吸与危重症医学中心2016年1月至2018年12月所有COPD患者1 210例,选择同期单纯COPD患者22例,观察COPD合并肺结核的临床特征,同时应用多因素Logistic回归分析COPD合并肺结核的危险因素。结果 所有COPD患者中,COPD合并肺结核患者120例,其患病率为9.91%,而其病死率为1.67%。在COPD合并肺结核中,合并其他疾病主要为肺癌、肺部感染、肺源性心脏病、高血压、冠心病、呼吸衰竭、糖尿病,患病率分别为20%、18.33%、17.50%、15.83%、12.5%、12.5%、5.83%; 在相关因素分析,结果显示COPD合并肺结核组在每年急性加重次数上显著多于对照组(P<0.05),两组间在性别比例、年龄、病程、吸烟比例以及吸烟时间上无统计学差异(P>0.05)。在多因素Logistic回归分析中,病程(>10年)、急性加重次数(>2次/年)、低蛋白血症是COPD合并肺结核的危险因素,OR值分别为8.455、45.607、14.990。结论 COPD合并肺结核后易合并其他疾病,增大其诊断和治疗的难度,及早关注其危险因素对其治疗和预后有临床意义。

Abstract:

Objective To explore the clinical characteristics and analyze the risk factors in chronic obstructive pulmonary disease(COPD)with tuberculosis. Methods 1 210 COPD cases were collected of department of respiratory and critical care medicine of Xinqiao Hospital all COPD cases in January 2016 to December 2018, and 22 COPD cases without other disease as control from January 2016 to December 2018. Meanwhile, the clinical characteristics and risk factors were analyzed by multi factor Logistic regression. Results 120 COPD with tuberculosis cases were found, which the morbidity and prevalence rate were 9.91% and 1.67%. In the investigation of co-morbidities, the result showed that lung cancer, Pulmonary infection, pulmonary heart disease, hypertension, coronary heart disease, respiratory failure, diabetes were major diseases, the prevalence rate of them was 20%, 18.33%, 17.50%, 15.83%, 12.5%, 12.5%, 5.83%, respectively. In the study of related factors, the result indicated that number of acute exacerbation was remarkably higher in experimental group than control groups(P<0.05). Nevertheless, there was no significant difference in age, sex, course, smoking rate and smoking time between the two groups(P>0.05). In the logistic regression analysis, the results showed that COPD course over 10 years, number of acute exacerbation over 2 times per year and hypoproteinemia were the risk factors for COPD with tuberculosis. Conclusion It is easy to be complicated with other diseases in COPD complicated with tuberculosis, which increases the difficulty of diagnosis and treatment to some extent. Therefore, it is necessary to pay attention to the risk factors for the treatment and prognosis.

参考文献/References:

1 Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey[J]. Am J Respir Crit Care Med, 2007, 176(8): 753-760.
2 Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
3 Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study[J]. Lancet Respir Med, 2018, 6(6): 421-430.
4 World Health Organization. Global tuberculosis report 2018[R]. Geneva: WHO, 2018.
5 Global Initiative for Chronic Obstructive Lung Disease(GOLD): Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease.(2020). http://www.goldcopd.org.
6 国家卫生健康委, 《中国结核病预防控制工作技术规范(2020年版)》, 2020.4.2.
7 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
8 陈华萍, 胡明冬, 张君国, 等. 慢性阻塞性肺疾病合并症及其对预后的影响[J]. 解放军医学杂志, 2020, 45(8): 834-839.
9 Elise G, George MI, Céline N, et al. Chronic obstructive pulmonary disease(COPD): neutrophils, macrophages and lymphocytes in patients with anterior tuberculosis compared to tobacco related COPD[J]. BMC Res Notes,2018, 11(1): 192.
10 Jardim Jr, Stirbulov R, Moreno D, et al. Respiratory medication use in primary careamong COPD subjects in four Latin American countries[J]. Int J Tuberc Lung Dis, 2017, 21(4): 458-465.
11 Pouldar D, Elsensohn A, Ortenzio F, et al. Nodular vasculitis in a patient with Crohn's disease on vedolizumab[J]. Am J Dermatopathol, 2018, 40(3): 36-37.
12 Lin JT, Xing B, Tang HP, et al. A multi-center retrospective study of clinical characteristics and hospitalization costs of patients hospitalized for asthma exacerbation in China during 2013-2014[J]. Chin J Tuber Respirat Dis, 2017, 40(11): 830-834.
13 Koul P, Dar H, Jan R, et al. Two-year mortality in survivors of acute exacerbations of chronic obstructive pulmonary disease: a North Indian study[J]. Lung India, 2017, 34(6): 511- 516.
14 吕 和, 王 政, 王 婷, 等. 非活动性肺结核并发慢性阻塞性肺疾病患者营养状况及营养风险分析[J]. 中国防痨杂志, 2020, 42(12): 1310-1312.
15 Wei ML, Zhao YJ, Qian ZY, et al. Pneumonia caused by Mycobacterium tuberculosis[J]. Microbes Infect, 2020, 22(6): 278-284.
16 Choi BJ, Prasad A, Gulati R, et al. Coronary endothelial dysfunctipon in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque[J]. Eur Heart J, 2013, 34(27): 2047-2054.
17 Trostdorf F, Landgraf C, Kablau M, et al. Increased endothelial cell apoptosis in symptomatic high-grade carotid artery atenosis: preliminary data[J]. Eur J Vase Endovasc Surg, 2007, 33(1): 6568.
18 Roversi S, Roversi P. Coronary artery disease concomitant with chronic obstructive pulmonary disease[J]. Eur J Clin Invest, 2014, 44(1): 93-102.
19 Liang BM, Xu ZB. Association of chronic obstructive pulmonary disease with coronary artery disease[J]. Chin Med J, 2013, 126(17): 3205-3208.
20 Agarwal S, Rokadia H. Burden of cardiovascular disease in chronic obstructive pulmonary disease[J]. Am J Prev Med, 2014, 47(2): 105-114.
21 Ferri C. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease[J]. High Blood Press Cardiovasc Prev, 2015, 22(2): 103-111.
22 石 菡. 老年慢性阻塞性肺疾病急性期合并肺结核感染的治疗方法及其疗效探讨[J]. 临床与病理杂志, 2016, 36(10): 1634-1639.
23 Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study[J]. Korean J intern Med, 2016, 31(5): 891-898.
24 Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies[J]. Lancet Respir Med, 2015, 3: 220-234.
25 Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis[J]. Semin Respir Crit Care Med, 2018, 39: 271-285.
26 Luo Y, Xue Ying, Mao LY, et al. Diagnostic value of T-SPOT.TB assay for tuberculous peritonitis: A Meta-analysis[J]. Front Med(Lausanne), 2020, 7: 585180.
27 Fei GJ, Zhang LF, Shu HJ. Values of different laboratory diagnostic approaches for tuberculous peritonitiss[J]. Acta Academiae Medicinae Sinica, 2018, 40(4): 534-538.
28 Zhou L, Shen S, He M, et al. T-SPOT.TB in the diagnosis of tuberculous peritonitis[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2013, 38(5): 526-531.
29 Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase(ADA)in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis[J]. J Clin Gastroenterol, 2006, 40(8): 705-710.
30 任成山, 林 辉, 杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 269-274.

备注/Memo

备注/Memo:

基金项目: 陆军军事医学创新工程专项(18CXZ002)
通信作者: 胡明冬,Email: huhanshandd@163.com

常用功能

更新日期/Last Update: 2021-12-20